Get the Stockscreener App
1.52
4.40%
-0.07
After Hours:
1.52
Caribou Biosciences Inc stock is traded at $1.52, with a volume of 800.23K.
It is down -4.40% in the last 24 hours and down -3.80% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$1.59
Open:
$1.59
24h Volume:
800.23K
Relative Volume:
0.70
Market Cap:
$142.07M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.0411
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
+2.70%
1M Performance:
-3.80%
6M Performance:
-15.08%
1Y Performance:
+17.83%
1-Day Range:
$1.47
$1.59
1-Week Range:
$1.47
$1.65
52-Week Range:
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.52 | 148.61M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Caribou Biosciences to Participate in Upcoming Investor Conferences - Investing News Network
CRISPR-focused Caribou set for fireside chats at 2 investor events - Stock Titan
What is Brookline Cap M's Forecast for CRBU FY2030 Earnings? - MarketBeat
Bond Watch: How does Caribou Biosciences Inc compare to its peersLayoff News & AI Enhanced Trading Signals - baoquankhu1.vn
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Caribou Biosciences (CRBU) and Boston Scientific (BSX) - The Globe and Mail
Caribou Biosciences (NASDAQ:CRBU) Shares Up 3.8%What's Next? - MarketBeat
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR - Investing News Network
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR® - The Manila Times
Off-the-shelf CAR-T data in lymphoma and myeloma head to 2026 Tandem - Stock Titan
Clear Street Initiates Caribou Biosciences(CRBU.US) With Buy Rating, Announces Target Price $13 - 富途牛牛
Caribou Biosciences a new buy at Clear Street on CAR-T pipeline - Seeking Alpha
Clear Street Initiates Coverage of Caribou Biosciences (CRBU) with Buy Recommendation - Nasdaq
Clear Street initiates coverage on Caribou Biosciences stock with Buy rating By Investing.com - Investing.com South Africa
Clear Street initiates coverage on Caribou Biosciences stock with Buy rating - Investing.com Nigeria
Guidance Update: Is PMTPRA a play on infrastructure spendingCEO Change & Intraday High Probability Setup Alerts - baoquankhu1.vn
Patterns Watch: How does Caribou Biosciences Inc compare to its peersEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Aug PreEarnings: Is Caribou Biosciences Inc a stock for growth or value investors2025 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
Trade Recap: Is Caribou Biosciences Inc stock good for income investorsJuly 2025 PreEarnings & Accurate Buy Signal Notifications - baoquankhu1.vn
Patterns Watch: Will ARAY benefit from rising consumer demandQuarterly Market Review & Weekly High Potential Alerts - baoquankhu1.vn
Take Profit: Is Caribou Biosciences Inc. stock good for income investorsJuly 2025 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
Caribou Biosciences Hits New 52-Week High at $3.54 - Markets Mojo
Trade Report: Can ULCC maintain its current growth rateTrade Analysis Report & Expert Curated Trade Setups - baoquankhu1.vn
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Sectors Review: Is Caribou Biosciences Inc a cyclical or defensive stockJuly 2025 Pullbacks & Real-Time Volume Spike Alerts - baoquankhu1.vn
Recap Report: Is Caribou Biosciences Inc benefiting from interest rate changes2025 Biggest Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN
BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why - sharewise.com
Caribou Biosciences (NASDAQ:CRBU) Shares Up 0.6%Should You Buy? - MarketBeat
Caribou Biosciences (CRBU) upgraded to buy: Here's why - MSN
Can Caribou Biosciences Inc. stock continue upward trendJuly 2025 PostEarnings & Risk Managed Trade Strategies - ulpravda.ru
What is the fair value of Caribou Biosciences Inc. stock now2025 Short Interest & Detailed Earnings Play Alerts - Улправда
How sustainable is Caribou Biosciences Inc. stock dividend payoutJuly 2025 Big Picture & Precise Buy Zone Identification - Улправда
Will Caribou Biosciences Inc. stock benefit from automation2025 Technical Patterns & Consistent Return Strategy Ideas - Улправда
Why Caribou Biosciences Inc. stock is rated strong buy2025 Market Sentiment & Growth Focused Stock Reports - Улправда
How Caribou Biosciences Inc. stock trades before earningsPortfolio Return Report & AI Based Trade Execution Alerts - Улправда
Can Caribou Biosciences Inc. stock sustain institutional interestMarket Sentiment Review & Low Drawdown Trading Techniques - Улправда
Can Caribou Biosciences Inc. stock sustain revenue growthM&A Rumor & Risk Adjusted Buy and Sell Alerts - Улправда
Income Plays: How analysts rate Caribou Biosciences Inc. stock todayMarket Risk Summary & High Conviction Buy Zone Picks - Улправда
Spotlight On Promising Penny Stocks In January 2026 - simplywall.st
Caribou Biosciences (CRBU) Gets a Buy from Bank of America Securities - The Globe and Mail
Aug Intraday: Can Caribou Biosciences Inc stock sustain revenue growthMarket Weekly Review & Daily Volume Surge Trade Alerts - moha.gov.vn
Caribou Biosciences (CRBU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Caribou Biosciences Inc stock remain a Wall Street favoriteGold Moves & Low Risk Entry Point Guides - moha.gov.vn
What valuation multiples suggest for Caribou Biosciences Inc. stockGap Fill Strategies & Affordable Growth Investments - bollywoodhelpline.com
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
Caribou Biosciences (NASDAQ:CRBU) Trading Up 2.4%Should You Buy? - MarketBeat
Why Caribou Biosciences Inc. stock is popular among millennialsJuly 2025 News Drivers & Weekly Momentum Picks - Улправда
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):